

MenQuadfi[®], Meningococcal (Groups A, C, Y, W) conjugate vaccine – Expanded indication

- On May 23, 2025, the [FDA approved](#) Sanofi's [MenQuadfi, Meningococcal \(Groups A, C, Y, W\) conjugate vaccine](#), for active immunization for the prevention of invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, W, and Y. **MenQuadfi is approved for use in individuals 6 weeks of age and older.**
 - MenQuadfi was previously approved for this indication in individuals 2 years of age and older.
 - MenQuadfi does not prevent *N. meningitidis* serogroup B disease.
- The approval of MenQuadfi for the expanded indication was based on immunogenicity studies comparing MenQuadfi to GSK's vaccine, [Menveo[®]](#).
- The most common adverse reactions (≥ 10%) with MenQuadfi use in infants 6 weeks through 23 months of age are as follows:
 - 4-dose series given at 2, 4, 6, and 12 through 18 months of age: tenderness, erythema, and swelling at the injection site; irritability, crying abnormal, drowsiness, appetite lost, fever, and vomiting
 - 2-dose series given at 6 through 7 months and 12 through 13 months of age: tenderness, erythema, and swelling at the injection site; irritability, crying abnormal, drowsiness, appetite lost, fever, and vomiting.
- MenQuadfi is administered as a 0.5 mL injection intramuscularly. Refer to the drug label for the complete dosing schedule.